NCT05275946View on ClinicalTrials.gov

Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 20, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions
Thyroid Cancer
Interventions
DRUG

Targeted alpha therapy

Single intravenous administration

Trial Locations (1)

565-0871

Osaka University Hospital, Suita

All Listed Sponsors
lead

Osaka University

OTHER

NCT05275946 - Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer | Biotech Hunter | Biotech Hunter